ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib, a Specifically Targeting the ABL Myristoyl Pocket (STAMP) kinase inhibitor, was approved by the FDA in 2021 for the treatment of patients with Ph+ CP-CML previously treated with ≥2 TKIs or with the T315I mutation [27, 33].